SCHEDULE: RTW Investments Reduces Oruka Therapeutics Stake to 4.3%

RTW Investments, LP and Roderick Wong, M.D. have reported a beneficial ownership of 4.3% in Oruka Therapeutics, Inc., as per their Schedule 13G/A filing.

Summary

• RTW Investments, LP and Roderick Wong, M.D. reported beneficial ownership of 2,058,148 shares of Oruka Therapeutics, Inc. Common Stock.
• This represents 4.3% of the company's outstanding shares.
• The percentage is calculated based on 48,409,232 shares outstanding as of October 31, 2025, as reported in the company's Form 10-Q filed on November 12, 2025.
• The shares are held by RTW Funds, for which RTW Investments acts as investment adviser and Dr. Wong is the Managing Partner and Chief Investment Officer.
• The filing is an Amendment No. 1 to a previous Schedule 13G filed on May 15, 2025.
• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative signal, as a reduction in a significant institutional stake below 5% can imply a lack of stronger conviction or a strategic shift by the investor, potentially impacting market perception.

Negatives

• The reduction of RTW Investments' beneficial ownership to 4.3% signifies a decrease in their stake below the 5% reporting threshold, which could be interpreted as a reduced conviction or strategic reallocation of capital by a significant institutional investor.

Future Outlook

No forward-looking statements or guidance from Oruka Therapeutics are provided in this filing.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by passive investors holding less than 20% of a company's stock. A reduction in stake below the 5% threshold, as seen here, typically triggers an amendment to reflect the change in reporting requirements. For biotechnology companies like Oruka Therapeutics, institutional investor activity is closely watched as a signal of confidence in their pipeline and future prospects.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure for beneficial ownership changes and does not contain information allowing for a direct comparison of Oruka Therapeutics' performance or results to industry benchmarks or specific comparable companies/projects.

Stakeholder Impact

• Shareholders may interpret the reduction in RTW Investments' stake as a negative signal, potentially leading to decreased investor confidence or selling pressure.
• Company management could face questions regarding the reasons for the institutional investor's reduced position.

Key Dates

Recommendation

The reduction of RTW Investments' stake below 5% is a notable event, suggesting a potential shift in their investment thesis or portfolio allocation. While not a complete divestment, it removes a significant institutional holder from the 5%+ reporting threshold, which could be perceived negatively by the market. Investors should 'hold' and monitor for further developments or explanations from either RTW or Oruka Therapeutics regarding this change, as it warrants further investigation into the underlying reasons rather than an immediate 'sell' without additional context.

Keywords

Oruka Therapeutics, RTW Investments, Roderick Wong, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake, SEC Filing, Biotechnology